Covectra’s new VRS solution automates compliance with standards; offers advanced verification capabilities; and is interoperable with other systems.
In November 2020, the FDA enforcement will begin as pharmaceutical distributors of regulated medicines will need to be compliant—or at least on a path to compliance—for the DSCSA saleable returns verification requirement. Implementation of these requirements is intended to enable the U.S. Food and Drug Administration (FDA) to better protect consumers from counterfeit, contaminated, or stolen drugs, and better detect and remove such drugs from the U.S. pharmaceutical supply chain. Wholesalers and distributors will need to verify the unique identifier of returned products before these can be placed into inventory for resale.
Covectra’s new VRS automates DSCSA compliance by managing the acceptance, formatting, and delivery of verification requests and responses for saleable pharmaceutical returns of serialized products in the U.S. It supports secure data exchange between manufacturers and distributors that confirms the authenticity of drug labels, determining if a returned product is in a state which allows it to be resold.
“VRS is a key defense mechanism to increase confidence that the U.S. drug supply is authentic, unadulterated, and safe for consumers, said Steve Wood, Covectra’s CEO. “Returned drugs can be fake, substandard and Covectra VRS provides an automated solution to combat this large issue.”